Coacervate formulations of cxcr-activating peptides for controlled release in ophthalmic and topical treatments
AssigneesUniversity of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs, Cornell University
InventorsAlan H. Wells, Shivalingappa Kottur Swamynathan, Yadong Wang
Life of this patent
Estimating the term…
Abstract
Controlled release coacervate formulations for slow, extended release of C-X-C chemokine receptor 3 (CXCR3) activating peptides are described. The controlled release compositions are designed for ophthalmic administration, such as by topical administration to the eye or by injection into the conjunctiva. Methods of treating dry eye disease and enhancing goblet cell density in the conjunctiva are also described.
Claims20
A composition, comprising one or more C-X-C chemokine receptor 3 (CXCR3)-activating peptides in a controlled release formulation for ophthalmic administration, wherein the controlled release formulation comprises a coacervate.
A composition, comprising a C-X-C chemokine receptor 3 (CXCR3)-activating peptide in a controlled release formulation for ophthalmic administration, wherein:
- the amino acid sequence of the CXCR3 activating peptide comprises
- (SEQ ID NO:
- 5)
- PESKAIKNLLKAVHKEMSKRSP;
- and
- the controlled release formulation comprises a coacervate comprising poly(ethylene arginyl aspartate diglyceride) (PEAD) and heparin.
Dependencies are inferred from the claim text.